The most common treatment‐emergent AEs in the MAD cohorts administered TransCon PTH were headache (12%), dizziness (10%), palpitations and catheter site phlebitis (each 8%), postural dizziness and upper respiratory tract infections (each 6%), and presyncope and musculoskeletal pain (each 6%). Here, PTH is linked to Recurrent upper respiratory tract infections.